Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 3/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14170147 | 0.88 | PIK3CD (0.51) | PIK3CDACEBIRC2MMP1MMP3 | |
| SCHEMBL14170355 | 0.85 | PIK3CD (0.57) | PIK3CDPIK3R1PIK3CAPOLBHDAC1 | |
| SCHEMBL14170329 | 0.80 | PIK3CD (0.46) | PIK3CDPOLBPER2 | |
| SCHEMBL12747512 | 0.79 | PIK3CD (0.35) | PIK3CDHDAC1ACEHDAC8HDAC6 | |
| SCHEMBL12747445 | 0.79 | PIK3CD (0.35) | PIK3CDHDAC1ACEHDAC8HDAC6 | |
| SCHEMBL14170735 | 0.79 | PIK3CD (0.45) | PIK3CDPOLB | |
| SCHEMBL14170670 | 0.79 | PIK3CD (0.45) | PIK3CDPOLBPRMT1 | |
| SCHEMBL14170429 | 0.78 | PIK3CD (0.43) | PIK3CDPOLB | |
| SCHEMBL14170812 | 0.78 | PIK3CD (0.44) | PIK3CDPOLB | |
| SCHEMBL14170230 | 0.78 | PIK3CD (0.44) | PIK3CDPOLBPRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168798-B2 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110137037-A1 | CASPASE INHIBITOR PRODRUGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-7879891-B2 | such as (S)-Carbazole-9-carboxylic acid 1-(3a-fluoromethyl-5-oxo-3a,5,6,6a-tetrahydro-furo[3,2-d]oxazol-2-yl)-2-methyl-propyl ester, used for the treatment of diseases related to inflammatory or degenerative conditions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| US-20070155718-A1 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155718-A1 | Caspase inhibitor prodrugs | CASP1, CASP5, CASP2 | PIK3CD 865/4885PIK3R1 1718/4885PIK3CA 696/4885 |
| US-20110137037-A1 | CASPASE INHIBITOR PRODRUGS | CASP1, CASP5, CASP2 | PIK3CD 865/4885PIK3R1 1718/4885PIK3CA 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.